{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:50Z","timestamp":1753891910360,"version":"3.41.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Acquired pure red cell aplasia (PRCA) has attracted more and more attention in hematology. PRCA usually caused by infection, autoimmune diseases, thymic carcinoma, or drugs, has not been reported by radioactive iodine. Here we report a case of PRCA after radioactive iodine therapies (two times, 100 mCi and 130 mCi each) in a patient with papillary thyroid carcinoma and follow up for two years. she was treatment with cyclosporine (100mg twice per day), stanozolol (2mg three times per day) and diammonium glycyrrhizinate (150mg three times per day), returned to the normal range in 2024.<\/jats:p>","DOI":"10.3389\/fonc.2025.1539586","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:20:46Z","timestamp":1750742446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pure red-cell aplasia after radioactive iodine treatment in a patient with papillary thyroid cancer and follow up for two years: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Rui","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-717140","article-title":"Pure red cell aplasia","volume":"128","author":"Means","year":"2016","journal-title":"Blood"},{"key":"B2","first-page":"18","article-title":"Update on pure red cell aplasia: etiology, diagnosis, and treatment","volume":"20","author":"Means","year":"2022","journal-title":"Clin Adv Hematol oncology: H&O"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2023.06.009","article-title":"Pure red cell aplasia: The second hundred years","volume":"366","author":"Means","year":"2023","journal-title":"Am J Med Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-2505-7_1","article-title":"Papillary thyroid carcinoma: current position in epidemiology, genomics, and classification","volume":"2534","author":"Lam","year":"2022","journal-title":"Methods Mol Biol (Clifton N.J.)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: A review","volume":"331","author":"Boucai","year":"2024","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-2505-7_16","article-title":"Radioactive iodine for papillary thyroid carcinoma","volume":"2534","author":"Chan","year":"2022","journal-title":"Methods Mol Biol (Clifton N.J.)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.19.22626","article-title":"Radioactive iodine therapy in differentiated thyroid cancer: 2020 update","volume":"215","author":"Ciarallo","year":"2020","journal-title":"AJR. Am J roentgenology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.929590","article-title":"Effect of \u00b9\u00b3\u00b9I therapy on complete blood count in patients with differentiated thyroid cancer","volume":"27","author":"Rui","year":"2021","journal-title":"Med Sci monitor: Int Med J Exp Clin Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000206843","article-title":"Acquired pure red cell aplasia associated with thyroid carcinoma: case report","volume":"69","author":"Iannucci","year":"1983","journal-title":"Acta haematologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0423","article-title":"Bone-marrow suppression in elderly patients following empiric radioiodine therapy: real-life data","volume":"29","author":"Duskin-Bitan","year":"2019","journal-title":"Thyroid"},{"key":"B11","first-page":"85","article-title":"Hematologic changes observed following I-131 therapy for thyroid carcinoma","volume":"4","author":"Haynie","year":"1963","journal-title":"J Nucl medicine: Off publication Soc Nucl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4158\/EP13172.OR","article-title":"Complete blood counts are frequently abnormal 1 year after dosimetry-guided radioactive iodine therapy for metastatic thyroid cancer","volume":"20","author":"Padovani","year":"2014","journal-title":"Endocrine practice: Off J Am Coll Endocrinol Am Assoc Clin Endocrinologists"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2124","article-title":"Bone marrow function after (131)I therapy in patients with differentiated thyroid carcinoma","volume":"100","author":"Prinsen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004451","article-title":"Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer","volume":"95","author":"Hu","year":"2016","journal-title":"Medicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1562851","article-title":"Effect of radioactive iodine therapy on hematological parameters in patients with thyroid cancer: systematic review and meta-analysis","volume":"16","author":"Berta","year":"2025","journal-title":"Front Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3544","article-title":"Effects of dosimetrically guided I-131 therapy on hematopoiesis in patients with differentiated thyroid cancer","volume":"101","author":"Bikas","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021398","article-title":"Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy","volume":"99","author":"Dong","year":"2020","journal-title":"Medicine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddac052","article-title":"Thyroid function, pernicious anemia and erythropoiesis: a two-sample Mendelian randomization study","volume":"31","author":"Kjaergaard","year":"2022","journal-title":"Hum Mol Genet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1539586\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:20:47Z","timestamp":1750742447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1539586\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":18,"alternative-id":["10.3389\/fonc.2025.1539586"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1539586","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"article-number":"1539586"}}